According to an FDA advisory panel, studies show that an experimental vaccine to prevent shingles can cut the rate of infection by about half in people 60 and older and help curb related pain.But
French drug company Sanofi Pasteur says early stage trials of an experimental vaccine against H5N1 bird flu have shown it provides a good immune response in humans and is safe.Sanofi Pas
Custom officers in the U.S. have seized 51 shipments of a fake anti-bird flu drug.The counterfeit medication had been shipped from Asia to an airmail facility in San Francisco, and Customs and Border Protection officers say each box contained 1
GenoMed, Inc. a Next Generation Disease Management company that uses its expertise in genomics to improve clinical outcomes in as many species as possible, announced today that two non-profit groups which care for w
Britannia Pharmaceuticals Limited announced today that U.S.-based Bertek Pharmaceuticals Inc., the branded subsidiary of Mylan Laboratories Inc has received
According to a new analysis by cardiologists at the Duke Clinical Research Institute, in the prescribing of common but powerful anti-clotting drugs, 42 percent of patients rushed to emergency rooms
Although the flu causes tens of thousands of deaths each year in the United States, vaccine to fight the illness is often in short supply when the flu season is at its peak. Now MIT-affiliated res
Researchers have demonstrated a technique that has the potential to reduce the toxicity of vaccines and to make smaller doses more effective, according to a study published in PLoS Pathogens.
This week California Governor Arnold Schwarzenegger appealed to Congress to allow Americans to import affordable prescription drugs from Canada and other countries. In a letter to Congressional leaders he acknowledged that "drug prices continue
SuperGen Inc. announced today that the Food and Drug Administration (FDA) has officially accepted the Orathecin? (rubitecan) capsules' New Drug Application (NDA) for filing. Orathecin, an investigation
ID Biomedical's proprietary cell culture-based manufacturing process is being developed as a possible future replacement to the classical egg-based manufacturing process currently used by all flu vaccine manufacturers, including ID Biomedical. The technology has particular application to manufacturing vaccine in the event of an influenza pandemic. This grant will allow ID Biomedical to further develop and conduct early-stage human trials of its cell culture-based influenza vaccine.
Commenting on the award, ID Biomedical's Senior Vice President of Development, Dr. Ronald Ellis said, "We are delighted to have received funding from the NIH to develop our cell-derived influenza vaccine. We had shown a few years ago that our cell-derived vaccine manufactured by a prototype process was comparable in terms of safety and immunogenicity to our licensed egg- derived vaccine, Fluviral(R). This NIH grant enables IDB to continue this development toward a commercial process that should produce a vaccine with a safety and immunogenicity profile that fully meets the requirements for any influenza vaccine. Moreover, the grant also enables the development of and manufacturing process for a pandemic vaccine, should one be needed."
Cell culture-based manufacturing technologies offer a number of potential advantages over traditional egg-based manufacturing processes, including a reduction in the time required to produce influenza vaccines and potentially improved effectiveness. Additionally, persons with egg allergies could take the vaccine, whereas egg-based vaccines are contra-indicated in this particular population.
"There is increasing concern around the world that an influenza pandemic, which could have disastrous consequences for public health, is imminent. The development of effective cell culture-based influenza vaccines is an important step forward both for addressing the pandemic threat as well as for use during the annual periods between pandemics. Cell culture technologies have the potential to overcome the problems associated with growing some influenza virus strains in eggs, and are a pathway to more rapid, and more efficient, production of influenza vaccines. The awarding of this grant is especially timely, considering the evolving situation with avian influenza in Asia," said Dr. John Treanor, Professor of Medicine, Infectious Diseases Unit, University of Rochester Medical Center.
"This award is not only important for the development of influenza vaccines that address pandemic strains of the flu virus, but in the long term, we need to consider the possibility that cell culture-derived flu vaccine could eventually supplant eggs as a source of vaccine," said Dr. Anthony Holler, ID Biomedical's Chief Executive Officer. "Accordingly, the development of our proprietary cell-based technology may be important for our annual injectable product, Fluviral, as well as our intra-nasal product in development, FluINsure(TM). In addition, this capability simply adds to the valuable portfolio of assets we have in the flu vaccine business. While we build an influenza franchise, it is important that we focus not just on the short term but also on the future."
http://www.idbiomedical.com/